BenevolentAI Results Presentation Deck
BEN-2293 for Atopic Dermatitis
• Atopic dermatitis (AD) is the most common chronic
inflammatory skin disease, characterized by intensely itchy,
red, and swollen skin(¹)
Affects 10-20% of children and up to 3% of adults (2)
O Approximately 60-70% of all cases present with
mild-moderate disease severity (3)
O
O
Prevalence is rising (3), with market value in 7MM
forecast to exceed $16.7 billion by 2030(4)
• BEN-2293 is expected to treat atopic dermatitis by:
inhibiting itch signaling and blocking nerve sensitization
(TrkA) in addition to inhibiting Th1 /Th2-mediated dermal
inflammation (TrkB, TrkC).
. Using our Molecular Design expertise we were able to design
a PanTrk inhibitor, equipotent against the 3 receptors
Sources: (1) Weidinger et al. Nat Rev Dis Primers 2018; (2) GlobalData Report 2018: Atopic Dermatitis:
Global Drug Forecast and Market Analysis to 2027; (3) Global Data Report 2018: Atopic Dermatitis:
Epidemiology Forecast to 2027; (4) GlobalData Report 2022: Atopic Dermatitis: Global Drug Forecast
and Market Analysis to 2030
TREATMENT FLOW
BenevolentAl Proprietary
Atopic Dermatitis Treatment Paradigm
Mild
Steroid Treatment
Current
Moderate
Calcineurin inhibitors
Future
PDE4 inhibitors
Topical JAKS
BEN-2293 (Pan Trk)
Other topicals
(tapinarof)
Severe
Immuno-
suppressants
Dupilumab
Other anti-IL13 mAbs
Oral JAKS
BEN-2293 will target Mild, Moderate and Severe AD
patients, addressing unmet need as a steroid sparing
alternative and in more severe patients undergoing
treatment with systemics (e.g. dupilumab) that require
add-on treatment
16View entire presentation